The Connexion Healthcare Rare Disease Center of Excellence is in Washington, DC, for the World Orphan Drug Congress USA 2015, April 22-24. This comprehensive event provides opportunities for orphan drug innovators to discuss ideas and strategies for the future of the industry. Connexion will be meeting with a variety of rare disease community leaders over the coming days, including patient advocacy groups, industry, US and EU government agencies (FDA, NIH/NCATS, INSERM, legislators), payers (MHPA, Aetna, Kaiser, Humana), large US and EU-based patient advocacy groups (NORD, EURORDIS, Global Genes), and large US hospitals and treatment centers.
The conference is for pharmaceutical industry, payers, regulators, and patient advocacy groups to talk about sustainability, pricing and reimbursement, commercialization, and global market access. More than 800 attendees from 40 countries are expected to attend. As Stephanie Okey, SVP at Genzyme explained in her speech, business can be aligned with good medicine, can address unmet needs, and can transform lives in the process.
To receive a summary of this year’s World Orphan Drug Congress, email Rare@connexionhealthcare.com.
About the Connexion Healthcare Rare Disease Center of Excellence
The Connexion Healthcare Rare Disease Center of Excellence specializes in communicating the science behind rare diseases and orphan drugs. We strategically partner with industry leaders in the rare disease community to proactively connect all stakeholders in launching products to underserved patient populations. Our team comprises skilled communications experts who plan, develop, and disseminate scientific communications based on their advanced knowledge of the science, the patient journey, healthcare providers, and the orphan drug approval process.
At Connexion, our cross-functional teams navigate complicated treatment and market landscapes by elucidating the appropriate pathways to brand success. We understand how brand strategy drives market share. Since launching its dedicated Rare Disease Center of Excellence, Connexion has developed prelaunch, launch, and postlaunch communications in numerous rare diseases and disorders: congenital and genetic, movement, metabolic, and lysosomal storage disorders; lung, blood, skin, and endocrine diseases; and rare cancers.
For further information regarding the Rare Disease Center of Excellence at Connexion Healthcare and how we can develop rare disease communications to differentiate therapies by their unique attributes, contact:
Susan Stein, MPH
Rare Disease Center of Excellence